The number of cancer survivors in the United States reached 18.6 million as of January 1 this year and is projected to exceed 22 million by 2035.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

Americans planning to travel outside the country should make sure they’re vaccinated against measles, the CDC says.

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Mitomycin plus BCG is as safe and effective as BCG alone, but the combination allows for a reduction in BCG doses and may help combat the BCG shortage.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

Adding rusfertide to standard care can reduce the need for phlebotomy and improve symptoms in patients with polycythemia vera who require frequent phlebotomies, data suggest.

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...